Compare Stocks: GTBP, ALPS, MGX, and TCRT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPS ALPS Group Inc Ordinary Share	$0.30 -7.7%	$0.53	$0.23 ▼ $15.00	$53.25M	-0.1	45,834 shs	123,075 shs
GTBP GT Biopharma	$0.28 -3.4%	$0.39	$0.26 ▼ $1.48	$13.12M	0.9	464,359 shs	535,620 shs
MGX Metagenomi	$1.21 -0.8%	$1.23	$1.13 ▼ $3.95	$46.47M	0.66	141,683 shs	66,485 shs
TCRT Alaunos Therapeutics	$1.88 -1.6%	$2.06	$1.67 ▼ $4.59	$46.65M	-1	9,605 shs	7,815 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPS ALPS Group Inc Ordinary Share	+0.06%	-23.21%	-35.96%	-58.61%	+32,019,900.00%
GTBP GT Biopharma	-3.72%	-11.10%	-19.92%	-33.57%	-78.73%
MGX Metagenomi	-0.81%	-0.81%	-1.61%	-2.40%	-34.41%
TCRT Alaunos Therapeutics	-1.04%	-3.29%	-6.83%	-23.60%	-15.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALPS ALPS Group Inc Ordinary Share	$0.30 -7.7%	$0.53	$0.23 ▼ $15.00	$53.25M	-0.1	45,834 shs	123,075 shs
GTBP GT Biopharma	$0.28 -3.4%	$0.39	$0.26 ▼ $1.48	$13.12M	0.9	464,359 shs	535,620 shs
MGX Metagenomi	$1.21 -0.8%	$1.23	$1.13 ▼ $3.95	$46.47M	0.66	141,683 shs	66,485 shs
TCRT Alaunos Therapeutics	$1.88 -1.6%	$2.06	$1.67 ▼ $4.59	$46.65M	-1	9,605 shs	7,815 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALPS ALPS Group Inc Ordinary Share	+0.06%	-23.21%	-35.96%	-58.61%	+32,019,900.00%
GTBP GT Biopharma	-3.72%	-11.10%	-19.92%	-33.57%	-78.73%
MGX Metagenomi	-0.81%	-0.81%	-1.61%	-2.40%	-34.41%
TCRT Alaunos Therapeutics	-1.04%	-3.29%	-6.83%	-23.60%	-15.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALPS ALPS Group Inc Ordinary Share	1.00	Sell	N/A	N/A
GTBP GT Biopharma	1.00	Sell	N/A	N/A
MGX Metagenomi	2.80	Moderate Buy	$6.33	423.42% Upside
TCRT Alaunos Therapeutics	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest GTBP, ALPS, MGX, and TCRT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/17/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/12/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$7.00
7/31/2026	TCRT Alaunos Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/23/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/8/2026	GTBP GT Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/8/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/7/2026	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00 ➝ $5.00
7/6/2026	ALPS ALPS Group Inc Ordinary Share	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
6/23/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/8/2026	MGX Metagenomi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 8/18/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALPS ALPS Group Inc Ordinary Share	$4.86M	10.12	N/A	N/A	($3.10) per share	-0.10
GTBP GT Biopharma	N/A	N/A	$0.01 per share	19.79	$0.23 per share	N/A
MGX Metagenomi	$25.21M	1.81	N/A	N/A	$4.22 per share	0.29
TCRT Alaunos Therapeutics	$3K	15,304.45	N/A	N/A	$0.93 per share	2.02

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALPS ALPS Group Inc Ordinary Share	-$2.01M	$0.33	0.90	N/A	N/A	N/A	N/A	N/A	N/A
GTBP GT Biopharma	-$28.35M	-$5.90	N/A	N/A	N/A	N/A	-194.73%	-142.11%	N/A
MGX Metagenomi	-$87.87M	-$2.49	N/A	N/A	N/A	-384.61%	-63.65%	-44.52%	N/A
TCRT Alaunos Therapeutics	-$4.18M	-$1.91	N/A	N/A	N/A	N/A	-192.66%	-140.32%	8/18/2026 (Estimated)

Latest GTBP, ALPS, MGX, and TCRT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	GTBP GT Biopharma	-$0.08	-$0.12	-$0.04	-$0.12	N/A	N/A
8/14/2026	Q2 2026	TCRT Alaunos Therapeutics	N/A	-$0.41	N/A	-$0.41	N/A	N/A
8/10/2026	Q2 2026	MGX Metagenomi	-$0.5531	-$0.73	-$0.1769	-$0.73	$3.01 million	($0.26) million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALPS ALPS Group Inc Ordinary Share	$0.37	125.17%	N/A	112.12%	N/A
GTBP GT Biopharma	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
TCRT Alaunos Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALPS ALPS Group Inc Ordinary Share	N/A	0.36	0.27
GTBP GT Biopharma	N/A	4.14	4.14
MGX Metagenomi	N/A	4.50	4.50
TCRT Alaunos Therapeutics	N/A	1.63	1.63

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALPS ALPS Group Inc Ordinary Share	27.90%
GTBP GT Biopharma	8.15%
MGX Metagenomi	N/A
TCRT Alaunos Therapeutics	27.72%

Insider Ownership

Company	Insider Ownership
ALPS ALPS Group Inc Ordinary Share	0.81%
GTBP GT Biopharma	1.18%
MGX Metagenomi	12.50%
TCRT Alaunos Therapeutics	16.14%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALPS ALPS Group Inc Ordinary Share	N/A	166.40 million	165.05 million	N/A
GTBP GT Biopharma	8	44.34 million	43.82 million	No Data
MGX Metagenomi	236	37.78 million	33.06 million	N/A
TCRT Alaunos Therapeutics	40	24.42 million	20.48 million	No Data

GTBP, ALPS, MGX, and TCRT Headlines

Recent News About These Companies

Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study

June 29, 2026 | markets.businessinsider.com

Alaunos Therapeutics, Inc.: Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | finanznachrichten.de

Alaunos reports positive preclinical obesity drug results across weight, liver, insulin markers

May 26, 2026 | msn.com

Alaunos Reports Broad Metabolic Improvements with ALN1003 in Obese Mouse Studies

May 26, 2026 | globenewswire.com

Alaunos Reports Preclinical ALN1003 Data Showing Effects on Insulin-Resistance-Related Biomarkers and Liver Histology in Diet-Induced Obesity Models

May 18, 2026 | globenewswire.com

Weight Loss Data From Obese Mice Looks Promising For Alaunos Therapeutics, But Shares Drop

March 2, 2026 | benzinga.com

Alaunos Reports Positive Preclinical Data for Obesity Candidate

March 2, 2026 | tipranks.com

Alaunos Therapeutics Announces Positive Preclinical Proof-of-Concept Data for ALN1003, a Differentiated Non-Hormonal Oral Treatment for Obesity and Related Metabolic Disorders

March 2, 2026 | globenewswire.com

Alaunos Therapeutics Reaches Settlement With MD Anderson Cancer

December 23, 2025 | tipranks.com

Alaunos Therapeutics files to sell 327,740 shares of common for holders

October 22, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics files $50M mixed securities shelf

August 21, 2025 | msn.com

Alaunos Therapeutics’ Innovative Glioblastoma Study Completes: Market Implications

August 12, 2025 | msn.com

Alaunos Therapeutics Appoints Holger Weis as New CEO

July 25, 2025 | theglobeandmail.com

Alaunos Therapeutics Taps Board Member Weis as Next CEO

July 2, 2025 | marketwatch.com

Alaunos Therapeutics, Inc. (TCRT) - Yahoo Finance

June 26, 2025 | finance.yahoo.com

Alaunos Therapeutics Raises $850,000 in Private Offering

June 26, 2025 | tipranks.com

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering - Morningstar

June 24, 2025 | morningstar.comM

Alaunos Therapeutics Announces $2.0 Million Registered Direct Offering

June 23, 2025 | globenewswire.com

Alaunos Therapeutics Amends Warrant Agreement with Mast Hill

June 10, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP, ALPS, MGX, and TCRT Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.30 -0.02 (-7.68%)

Closing price 04:00 PM Eastern

Extended Trading

$0.28 -0.01 (-3.59%)

As of 07:53 PM Eastern

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

GT Biopharma NASDAQ:GTBP

$0.28 -0.01 (-3.37%)

Closing price 04:00 PM Eastern

Extended Trading

$0.28 0.00 (-0.15%)

As of 07:59 PM Eastern

GT Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its proprietary Tri-specific Killer Engager (TriKE) fusion protein immune cell engager technology platform. It develops GTB-3550, a single-chain tri-specific recombinant fusion protein conjugate that is in Phase I clinical trial for the treatment of myelodysplastic syndromes, refractory/relapsed acute myeloid leukemia or advanced systemic mastocytosis, and CD33+ malignancies. The company is developing GTB-3650, which is in preclinical studies that target CD33 on the surface of myeloid leukemias; and GTB-5550 that is in preclinical studies for treating patients with B7-H3 positive solid tumors. GT Biopharma, Inc. has a co-development partnership agreement with Altor BioScience Corporation for the clinical development of a 161533 (GTB-3550) TriKE fusion protein for cancer therapies; and a license agreement with the Regents of the University of Minnesota to develop and commercialize cancer therapies using TriKE technology. The company was formerly known as OXIS International, Inc. and changed its name to GT Biopharma, Inc. in July 2017. GT Biopharma, Inc. was incorporated in 1965 and is based in Brisbane, California.

Metagenomi NASDAQ:MGX

$1.21 -0.01 (-0.82%)

Closing price 04:00 PM Eastern

Extended Trading

$1.21 +0.00 (+0.33%)

As of 07:50 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Alaunos Therapeutics NASDAQ:TCRT

$1.88 -0.03 (-1.57%)

Closing price 03:54 PM Eastern

Extended Trading

$2.00 +0.12 (+6.17%)

As of 06:05 PM Eastern

Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers. The company is also developing hunTR, a human neoantigen TCR discovery engine; and Sleeping Beauty Gene Transfer Platform, a non-viral genetic engineering technology. The company was founded in 2003 and is headquartered in Houston, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GTBP, ALPS, MGX, and TCRT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GTBP, ALPS, MGX, and TCRT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GTBP, ALPS, MGX, and TCRT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP, ALPS, MGX, and TCRT Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

GT Biopharma NASDAQ:GTBP

Metagenomi NASDAQ:MGX

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GTBP, ALPS, MGX, and TCRT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GTBP, ALPS, MGX, and TCRT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GTBP, ALPS, MGX, and TCRT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

GTBP, ALPS, MGX, and TCRT Company Descriptions

ALPS Group Inc Ordinary Share NASDAQ:ALPS

GT Biopharma NASDAQ:GTBP

Metagenomi NASDAQ:MGX

Alaunos Therapeutics NASDAQ:TCRT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools